AccuStem Sciences is a seed startup. 2 investors tracked. Status: possibledead.
Based in the United States, AccuStem Sciences is a startup founded in 2020. Its most recent tracked round is Seed. Brouky records 1 investor associated with the company.
AccuStem Sciences is a clinical-stage diagnostics company focused on developing genomic tests to guide cancer care decisions. Its lead products include MSC, a blood-based assay for lung cancer risk assessment, and StemPrintER, a test predicting breast cancer recurrence risk.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.